# Suresh Alaparthy

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/suresh-alaparthy/

## Facts

| Field | Value |
| --- | --- |
| Citations | 9,549 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 14 |
| i10-index | 16 |
| Last Known Institution | Bristol-Myers Squibb (United States) |
| OpenAlex ID | https://openalex.org/A5100920531 |
| Works | 22 |

## Researcher papers

- [Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer](https://scholariq.org/papers/safety-and-activity-of-anti-pd-l1-antibody-in-patients-with-advanced-cancer/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Researcher university

- [Bristol-Myers Squibb (United States)](https://scholariq.org/institutions/bristol-myers-squibb-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.